We read with interest the recent article in IOVS by De Filippo and colleagues 1 ''Identification of Novel G Protein-Coupled Receptor 143 Ligands as Pharmacologic Tools for Investigating X-Linked Ocular Albinism'' as we have extensive experience in this area of research. We are writing to point out a critical design flaw with the study that complicates interpretation of the data presented in the article.
In several other cell types (including Chinese hamster ovary [CHO] ) transfected to overexpress GPR143, we observed low background activity of GPR143 in media containing 1 lM tyrosine and a response to L-DOPA that is immediate and robust ( Figure) . In contrast, De Filippo and colleagues 1 report a very high level of constitutive activity of GPR143 and lack of response to L-DOPA. This is not surprising given the 213 lM tyrosine in the media used in their study. Tyrosine, dopamine, and L-DOPA all compete for the same GRP143 binding site. 2 Also not unexpected is that De Filippo and colleagues were only able to screen for antagonists in their assay given the continuous activation of receptor (likely by tyrosine in the commercial medium chosen). Instead of simply making custom media, the authors use a mutant form of GPR143 that remains at the plasma membrane due to cytoplasmic loop mutations that inhibit GPR143 endocytosis. For their assay to be useful to screen for agonists, we think they simply need to adjust their culture media, reducing the tyrosine concentration, which would abrogate the need to use the mutant receptor with unknown agonist activity.
FIGURE. FLIPR fluorometric imaging analysis of intracellular calcium in CHO cells expressing recombinant GPR143. CHO cells were transfected to express human GPR143 and maintained in tyrosine-free DMEM supplemented with 10% dialyzed fetal bovine serum (devoid of free amino acids) and 1 lM tyrosine. Cells were incubated as described for the FLIPR Calcium Assay kit, and fluorescence was measured using a Flex Station 3 (Molecular Devices, Sunnyvale, CA, USA). After a stable baseline measurement was achieved, L-DOPA was added to a final concentration of 1.0 lM. Control cells were maintained in normal medium without a ligand and illustrate the stable baseline in the absence of an activating ligand.
